<DOC>
	<DOCNO>NCT02215005</DOCNO>
	<brief_summary>The main objective investigate effect concurrent dose 10 mg ramipril 80 mg telmisartan multiple-dose pharmacokinetics telmisartan ramipril . Therefore relative bioavailability telmisartan ramipril give combination determine comparison either telmisartan ramipril give alone .</brief_summary>
	<brief_title>Steady State Pharmacokinetics Telmisartan , Ramipril Combination Following Repeated Oral Doses Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Healthy male female accord follow criterion base upon complete medical history , include physical examination , vital sign ( Blood Pressure ( BP ) , Pulse Rate ( PR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test Age ≥18 ≤55 year Body mass index ( BMI ) ≥18.5 ≤29.9 kg/m2 Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial ( especially unspecific induce agent like St.John´s wort ( Hypericum perforatum ) inhibitor like cimetidine ) drug prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial drug trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Alcohol abuse ( 60 g/day ) inability stop alcoholic beverage 24 hour prior dose last sampling time point Drug abuse Blood donation ( 100 mL within four week prior administration trial drug trial ) Excessive physical activity ( within one week prior administration trial drug trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor torsade de pointes ( e.g. , heart failure , hyperkalaemia , hypokalemia , family history Long QT Syndrome ) Any history relevant low blood pressure Supine blood pressure screen systolic &lt; 110 mm Hg diastolic &lt; 60 mm Hg History urticaria History angioneurotic edema Hereditary fructose intolerance Salt and/or volume depletion For female subject : Pregnancy plan become pregnant study within 1 month study completion Positive pregnancy test Not willing unable use reliable method contraception implant , injectables , combine oral contraceptive , sterilisation , intrauterine device , double barrier method , sexual abstinence least 1 month , vasectomise partner method contraception least 6 month prior participation trial , 1 month completion/termination trial Chronic use oral contraception contain ethinyl estradiol method contraception Currently lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>